Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of mefatinib in advanced non-small cell lung cancer with rare EGFR mutations
ChiCTR2000029058Phase 2Recruiting
- Sponsor
- Eastern Theater General Hospital
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mifanertinib in non-small cell lung cancer (NSCLC), sponsored by Eastern Theater General Hospital. Primary endpoint: Overall response rate. Started Jul 2018; status: recruiting.
02
Drugs
mifanertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029058.